91 completed, 13 unknown, 9 recruiting, 8 active not recruiting. 58 Phase 3, 56 Phase 2, 22 Phase 1, 6 Not applicable.
Follow this drug Literature Review of Daunorubicin Hydrochloride trials Research Report on Daunorubicin Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Cytarabine - Core Binding Factor Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2026-09-28 | 2026-10-20 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 53 | 2025-10-10 | 2026-10-13 |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 335 | 2024-09-25 | 2026-10-21 |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2024-09-13 | 2026-10-16 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-10-21 |
| A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia Venetoclax, Azacitidine, Cytarabine - Acute Myeloid Leukemia | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 70 | 2023-07-25 | 2026-09-17 |
| Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride - B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 24 | 2022-03-17 | 2026-05-28 |
| BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2021-02-17 | 2026-06-12 |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 1400 | 2020-07-21 | 2026-09-17 |
| Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Gilteritinib, Midostaurin, Daunorubicin - Acute Myeloid Leukemia | Phase 2 | Completed | PrECOG, LLC. | 181 | 2019-12-06 | 2026-07-23 |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Recruiting | Children's Oncology Group | 5951 | 2019-10-31 | 2026-08-25 |
| Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement Cytarabine, Daunorubicin, Daunorubicin Hydrochloride - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2019-04-10 | 2025-06-18 |
| Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Cytarabine, Daunorubicin Hydrochloride - Acute Myeloid Leukemia | Phase 1 | Completed | Uma Borate | 21 | 2019-03-13 | 2026-05-15 |
| Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients Cytarabine, Daunorubicin Hydrochloride, Selinexor - Untreated Adult Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Wake Forest University Health Sciences | 57 | 2018-02-02 | 2026-08-20 |
| Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia Allopurinol, Cytarabine, Daunorubicin Hydrochloride - B Acute Lymphoblastic Leukemia | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 303 | 2017-09-20 | 2026-10-19 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 352 | 2017-08-08 | 2026-10-05 |
| Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Azacitidine, Biospecimen Collection, Computed Tomography - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2017-04-01 | 2025-02-27 |
| Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Bone Marrow Aspiration and Biopsy, Cytarabine, Daunorubicin Hydrochloride - Acute Myeloid Leukemia | Phase 1 | Completed | Wake Forest University Health Sciences | 40 | 2016-11-01 | 2026-08-03 |
Showing 20 of 132. Sign in to see all of them.
Leukemia (68) · Leukemia, Myeloid, Acute (43) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (37) · Leukemia, Myelomonocytic, Acute (26) · Leukemia, Monocytic, Acute (24) · Congenital Abnormalities (22) · Leukemia, Erythroblastic, Acute (21) · Leukemia, Megakaryoblastic, Acute (20) · Burkitt Lymphoma (15) · Lymphoma (13) · Leukemia, Biphenotypic, Acute (10) · Myelodysplastic Syndromes (10) · Anemia, Refractory, with Excess of Blasts (8) · Myeloproliferative Disorders (7) · Leukemia, Basophilic, Acute (6)
National Cancer Institute (NCI) (32) · Children's Oncology Group (30) · European Organisation for Research and Treatment of Cancer - EORTC (6) · SWOG Cancer Research Network (5) · Medical Research Council (4) · Memorial Sloan Kettering Cancer Center (4) · Alliance for Clinical Trials in Oncology (3) · Wake Forest University Health Sciences (3) · City of Hope Medical Center (2) · Eastern Cooperative Oncology Group (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · National Institutes of Health Clinical Center (CC) (2) · Roswell Park Cancer Institute (2) · University Hospital Schleswig-Holstein (2)
United States (97) · Canada (40) · Australia (29) · Puerto Rico (23) · Switzerland (18) · New Zealand (14) · Germany (12) · United Kingdom (10) · France (9) · Netherlands (9) · Italy (7) · Belgium (6) · Czechia (6) · Austria (5) · Israel (4)
Alan K. Burnett, MD, FRCP (3) · Guido Marcucci (3) · Thomas R. Chauncey, MD, PhD (3) · Alan S. Gamis, MD, MPH (2) · Bayard Powell (2) · Ian Trevor Magrath, MD, FRCP, FRCPath (2) · Ibrahim Aldoss (2) · Julio C. Barredo, MD (2) · Martin Schrappe, MD, PhD (2) · Minnie Abromowitch, MD (2) · Naomi J. Winick, MD (2) · Robert A. Zittoun, MD (2) · Roberto Foa, MD (2) · Roel Willemze, MD, PhD (2) · Tim O.B. Eden, MB, BS, FRCPE, FRCP, FRCPCH, F (2)
PMID 36184192, PMID 31171508, PMID 31375516, PMID 36815378, PMID 38295280, PMID 42085603, PMID 23007406, PMID 33242441, PMID 37267439, PMID 23233662, PMID 24383844, PMID 24970932, PMID 25527568, PMID 26913693, PMID 29926156, PMID 30523055, PMID 32589970, PMID 33496745, PMID 34048072, PMID 34162404, PMID 34596937, PMID 36603187, PMID 37890117, PMID 38446568, PMID 39121442, PMID 40294366, PMID 41671463, PMID 42085640, PMID 12011123, PMID 12111109, PMID 12153596, PMID 12239143, PMID 12694250, PMID 12780755, PMID 15087948, PMID 15154634, PMID 15353542, PMID 15368546, PMID 15637138, PMID 15801953, PMID 15952999, PMID 16105981, PMID 16136166, PMID 16333838, PMID 16484584, PMID 16556888, PMID 16556894, PMID 16609069, PMID 16809737, PMID 17032921
U10CA098543 (14), U10CA180886 (12), U10CA031946 (11), U10CA180821 (6), U10CA032102 (5), U10CA180888 (4), P30CA006973 (3), P30CA012197 (3), 2009 (2), P30CA033572 (2), U01CA070095 (2), U10CA021115 (2), 2004 (1), 2017 (1), N01CM00070 (1)